Faced with unprecedented cancer treatment costs and complexity, employers are putting all benefit plans and management ideas on the table for review in their quest for quality and value. They are doing so with information from every cancer treatment stakeholder but one: biopharmaceutical manufacturers (biopharma).
The objective of this Oncology Management & Benefit Design report is to identify the role and opportunities for biopharma to engage in defining sustainable cancer management solutions, and ultimately make their case for ongoing product access and appropriate reimbursement. The key findings reflect interviews conducted with 28 leading edge jumbo employers and 7 additional healthcare stakeholders (3 provider organizations, along with a health plan, PBM, Rx group purchasing coalition and a national guideline organization).
Subscribers can use this research to anticipate changes in employer purchaser approaches to cancer care benefits, tailor value proposition messaging and build support materials and tools that will resonate with employers.
A purchase of the Oncology Management and Benefit Design Report includes:
Contact Sarah Daley at 314-656-2384 for pricing, packages and additional details.